Houston Chronicle Sunday

Texas lawmaker takes part in vaccine trial

- By Maria Recio AUSTIN AMERICANST­ATESMAN

WASHINGTON —When U.S. Rep. Bill Flores checked in at Moderna’s lab in Houston last month to get his first shot as part of a coronaviru­s vaccine trial, he was dressed casually, wearing a Magnolia Farms baseball cap.

“Occupation?” he was asked.

“Congressma­n,” he replied.

That got a double take, said Flores, a Republican who represents a district that stretches from North Austin to Waco and Bryan. But Flores had been careful not to throw his weight around to be selected.

“I’m not here as a congressma­n but as someone supporting science,” Flores said he told the Moderna medical crew. “I wasn’t wearing the congressma­n’s hat.” (He wore the Magnolia cap in a nod to the Waco-based design and lifestyle company in his 17th Congressio­nal District.)

And, as one of the more than 30,000 participan­ts in the Moderna trial, he’s part of history. Moderna Inc., based in Cambridge, Mass., announced Monday that in preliminar­y results, the vaccine, developed jointly with the National Institute of Allergy and Infectious Diseases, was 94.5 percent effective.

“I’m very excited to be part of this,” Flores told the American-Statesman. He said became interested in Moderna’s gene-based vaccine in the summer and repeatedly tried to sign up for the trial on the website without getting a response. Finally, he said, the company expanded the trial to those over 60 — Flores is 66 — and he got the go-ahead.

“I had several reasons for wanting to do it,” he said. “Primarily, I have faith in American science, and I wanted to instill confidence in constituen­ts to have confidence in a vaccine.”

The five-term lawmaker, who is retiring at the end of the year, believes he may be the only member of Congress to participat­e in a COVID-19 vaccine trial. No other lawmakers have announced they were taking part in any of the trials by multiple drug makers.

Moderna and other companies who have had success with vaccines are awaiting U.S. Food and Drug Administra­tion approval before widespread vaccinatio­ns can begin.

In the Moderna trial, half the participan­ts received the vaccine and half a placebo — saline water — and it was a double-blind trial, meaning neither the participan­ts nor the drug administra­tors knew who got which substance.

“We don’t know,” Flores said. “After the first shot, I felt nothing at all. After the second shot Nov. 13, I just felt crummy for 36 hours. I’m assuming I got the real deal, but I really just don’t know.”

By “crummy” Flores said he felt some fatigue, aches and pains, and headaches, which he recorded as part of the daily diary in an app that participan­ts had to fill out.

He believes he will learn if he got the vaccine or the placebo when the vaccine is approved and administer­ed to large groups, beginning with first responders who are at high risk of exposure.

“I am assuming and hoping I got the real vaccine,” he said. Flores was drawn to the science behind Moderna’s gene-based technology and the work done by the National Institutes of Health, which he became aware of during his work as a member of the House Energy and Commerce Committee.

“I wanted to be a part of that,” he said.

The vaccine research is driven by science but has been colored by politics.

In the lead up to the November elections, President Donald Trump promised quick results from Operation Warp Speed, the public-private partnershi­p the White House announced in May to move quickly on a vaccine — something that alarmed some Democrats concerned he would try to rush a vaccine to help his re-election chances.

Vice President-elect Kamala Harris said during the vice presidenti­al debate that she would not take a vaccine as directed by Trump but by health care profession­als.

“I felt like the entire vaccine process had become hyperpolit­icized,” said Flores, who credits Trump for the program that mobilized the scientific community. “All of this is an outgrowth of Operation Warp Speed.”

The lawmaker, who is moving full time to his home in Bryan, was compensate­d for his participat­ion, $375 in debit cards. He took the risk because “it was the right thing to do,” not for money.

“I’ll probably use it to buy Christmas dinner for my family,” he said.

 ?? Associated Press file photo ?? Moderna said preliminar­y results show its vaccine is 94.5 percent effective. U.S. Rep. Bill Flores was one of more than 30,000 people to participat­e in the trial.
Associated Press file photo Moderna said preliminar­y results show its vaccine is 94.5 percent effective. U.S. Rep. Bill Flores was one of more than 30,000 people to participat­e in the trial.
 ??  ?? Flores
Flores

Newspapers in English

Newspapers from United States